Oncology

News

ESMO: GSK, iTeos bring some optimism back to TIGIT

GSK and iTeos anti-TIGIT antibody belrestotug showed efficacy in a phase 2 trial in PD-L1-positive non-small cell lung cancer (NSCLC), providing some much-needed positive news for the belea

News

ESMO: Enhertu shows its worth in brain metastases

Women with HER2-positive breast cancer can be treated with AstraZeneca and Daiichi Sankyo's Enhertu, regardless of whether their cancer has spread to the brain, according to a new study.

Oncology

ESMO 2024 – Today’s oncological roots are branching

What could a tree possibly reveal about the European Society for Medical Oncology (ESMO)?

News

WCLC: Biomarker could guide Dato-DXd use in lung cancer

A biomarker could help identify patients with lung cancer who are most likely to benefit from treatment with AstraZeneca and Daiichi Sankyo's TROP2-directed drug datopotamab deruxtecan (Dat

News

WCLC: Summit trumpets data with Keytruda challenger

MSD's PD-1 inhibitor Keytruda has ruled the immunotherapy of non-small cell lung cancer (NSCLC) for many years, but a bispecific antibody from Summit Therapeutics and partner Akeso looks li

News

WCLC: MSD/Daiichi build case for phase 3 ADC for lung cancer

MSD and Daiichi Sankyo have revealed some of the clinical data that prompted them to start pivotal testing of ifinatamab deruxtecan (I-DXd) in patients with previously treated, extensive-st

ESMO: GSK, iTeos bring some optimism back to TIGIT

ESMO: Enhertu shows its worth in brain metastases

ESMO 2024 – Today’s oncological roots are branching

WCLC: Biomarker could guide Dato-DXd use in lung cancer

WCLC: Summit trumpets data with Keytruda challenger

WCLC: MSD/Daiichi build case for phase 3 ADC for lung cancer

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Oncology

Editor's Picks